

# George N Dalekos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/993460/publications.pdf>

Version: 2024-02-01

194  
papers

9,487  
citations

41258

49  
h-index

45213

90  
g-index

197  
all docs

197  
docs citations

197  
times ranked

8260  
citing authors

#	ARTICLE	IF	CITATIONS
1	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 169-176.	3.6	1,553
2	Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta. <i>New England Journal of Medicine</i> , 2011, 364, 322-331.	13.9	401
3	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 800-806.	1.8	358
4	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
5	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1752-1760.	15.2	353
6	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	3.6	239
7	Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. <i>Hepatology</i> , 2014, 60, 87-97.	3.6	234
8	Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. <i>Journal of Hepatology</i> , 2011, 55, 636-646.	1.8	163
9	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	1.8	158
10	Review article: autoimmune hepatitis - current management and challenges. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 887-913.	1.9	146
11	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , 2015, 62, 363-370.	1.8	138
12	Autoimmune hepatitis, one disease with many faces: Etiopathogenetic, clinico-laboratory and histological characteristics. <i>World Journal of Gastroenterology</i> , 2015, 21, 60.	1.4	136
13	Hepatocyte autotaxin expression promotes liver fibrosis and cancer. <i>Hepatology</i> , 2017, 65, 1369-1383.	3.6	134
14	Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment. <i>Journal of Translational Internal Medicine</i> , 2015, 3, 43-50.	1.0	128
15	An open label trial of anakinra to prevent respiratory failure in COVID-19. <i>ELife</i> , 2021, 10, .	2.8	127
16	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010, 35, 436-442.	3.0	123
17	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , The, 2021, 3, e690-e697.	2.2	121
18	Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. <i>Journal of Autoimmune Diseases</i> , 2004, 1, 2.	1.0	114

#	ARTICLE	IF	CITATIONS
19	Adipokines as mediators of endothelial function and atherosclerosis. <i>Atherosclerosis</i> , 2013, 227, 216-221.	0.4	111
20	Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study. <i>Journal of Hepatology</i> , 2013, 59, 949-956.	1.8	107
21	Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. <i>Liver International</i> , 2010, 30, 430-437.	1.9	96
22	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	1.8	88
23	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , 2019, 105, 102328.	3.0	86
24	A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1035-1047.	1.9	80
25	Alpha-actinin: A multidisciplinary protein with important role in B-cell driven autoimmunity. <i>Autoimmunity Reviews</i> , 2011, 10, 389-396.	2.5	78
26	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	1.8	75
27	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74
28	Clinical and virological heterogeneity of hepatitis delta in different regions worldwide: The Hepatitis Delta International Network (<scp>HDIN</scp>). <i>Liver International</i> , 2018, 38, 842-850.	1.9	72
29	Spontaneous spondylodiscitis: presentation, risk factors, diagnosis, management, and outcome. <i>International Journal of Infectious Diseases</i> , 2009, 13, 564-569.	1.5	70
30	Transcriptomic similarities and differences in host response between SARS-CoV-2 and other viral infections. <i>IScience</i> , 2021, 24, 101947.	1.9	70
31	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	1.8	69
32	DARING-B: Discontinuation of Effective Entecavir or Tenofovir Disoproxil Fumarate Long-Term Therapy before HBsAg Loss in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2018, 23, 677-685.	0.6	68
33	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1127-1136.	1.9	66
34	Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. <i>European Journal of Clinical Investigation</i> , 2003, 33, 161-168.	1.7	65
35	Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 67-74.	0.8	64
36	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.2	64

#	ARTICLE	IF	CITATIONS
37	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. <i>Journal of Hepatology</i> , 2022, 76, 841-849.	1.8	64
38	Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score?. <i>Digestive and Liver Disease</i> , 2010, 42, 807-812.	0.4	63
39	Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2342-2349.e2.	2.4	57
40	Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. <i>Liver International</i> , 2007, 27, 1226-1231.	1.9	56
41	Diagnostic Relevance and Clinical Significance of the New Enhanced Performance M2 (MIT3) ELISA for the Detection of IgA and IgG Antimitochondrial Antibodies in Primary Biliary Cirrhosis. <i>Journal of Clinical Immunology</i> , 2007, 27, 378-387.	2.0	56
42	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	3.6	55
43	Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?. <i>Liver International</i> , 2012, 32, 544-553.	1.9	54
44	Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. <i>Autoimmunity</i> , 2013, 46, 471-479.	1.2	54
45	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54
46	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. <i>Journal of Hepatology</i> , 2022, 76, 1042-1050.	1.8	54
47	Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. <i>Clinical Immunology</i> , 2006, 119, 203-212.	1.4	53
48	Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. <i>Clinical and Experimental Medicine</i> , 2014, 14, 121-131.	1.9	53
49	Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. <i>Hepatology</i> , 2007, 45, 1583-1583.	3.6	51
50	Emergence of Escherichia coli sequence type 410 (ST410) with KPC-2 $\beta$ -lactamase. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 247-250.	1.1	51
51	Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2005, 24, 251-260.	3.0	49
52	The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. <i>Journal of Autoimmune Diseases</i> , 2007, 4, 3.	1.0	49
53	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	1.8	48
54	Adiponectin: A New Independent Predictor of Liver Steatosis and Response to IFN- $\alpha$ Treatment in Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2008, 103, 605-614.	0.2	47

#	ARTICLE	IF	CITATIONS
55	Occult hepatitis B virus infection in patients with autoimmune liver diseases. <i>Liver International</i> , 2009, 29, 434-442.	1.9	47
56	Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1359-1368.	1.0	47
57	Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. <i>Hepatology Research</i> , 2019, 49, 96-104.	1.8	45
58	Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever. <i>Journal of Rheumatology</i> , 2017, 44, 102-109.	1.0	44
59	Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. <i>Liver International</i> , 2015, 35, 660-672.	1.9	42
60	Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. <i>Annals of Hepatology</i> , 2014, 13, 127-135.	0.6	40
61	Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 35-42.	0.8	39
62	Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 118-126.	1.0	38
63	IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases. <i>Journal of Clinical Immunology</i> , 2008, 28, 501-511.	2.0	37
64	Geoeidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. <i>European Journal of Internal Medicine</i> , 2017, 42, 81-88.	1.0	37
65	Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. <i>World Journal of Gastroenterology</i> , 2010, 16, 225.	1.4	36
66	JAK Inhibitors and Oxidative Stress Control. <i>Frontiers in Immunology</i> , 2019, 10, 2814.	2.2	36
67	SARS-CoV-2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID-19 Vaccination. <i>Hepatology Communications</i> , 2022, 6, 889-897.	2.0	36
68	Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. <i>Clinica Chimica Acta</i> , 2007, 380, 118-121.	0.5	34
69	Oxidative stress and antioxidant status in patients with autoimmune liver diseases. <i>Redox Report</i> , 2015, 20, 33-41.	1.4	34
70	Review article: unanswered clinical and research questions in autoimmune hepatitis – conclusions of the International Autoimmune Hepatitis Group Research Workshop. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 528-536.	1.9	33
71	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1545-1553.	1.8	33
72	Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. <i>Annals of Gastroenterology</i> , 2018, 32, 1-23.	0.4	32

#	ARTICLE	IF	CITATIONS
73	JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren's Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 58, 182-193.	2.9	32
74	Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. <i>Journal of Hepatology</i> , 2021, 74, 312-320.	1.8	31
75	Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. <i>World Journal of Hepatology</i> , 2013, 5, 387.	0.8	31
76	Molecular diagnostic testing for primary biliary cholangitis. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1001-1010.	1.5	30
77	Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. <i>International Journal of Infectious Diseases</i> , 2009, 13, e157-e160.	1.5	27
78	On-treatment prediction of sustained response to peginterferon alfa-2a for HBsAg-negative chronic hepatitis B patients. <i>Liver International</i> , 2015, 35, 1540-1548.	1.9	27
79	Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. <i>JHEP Reports</i> , 2020, 2, 100123.	2.6	27
80	Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients. <i>World Journal of Gastroenterology</i> , 2020, 26, 5130-5145.	1.4	27
81	Current clinical, laboratory, and treatment outcome characteristics of visceral leishmaniasis: results from a seven-year retrospective study in Greece. <i>International Journal of Infectious Diseases</i> , 2015, 34, 46-50.	1.5	26
82	COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. <i>European Journal of Internal Medicine</i> , 2017, 38, 83-88.	1.0	26
83	NAFLD and autoimmune hepatitis: Do not judge a book by its cover. <i>European Journal of Internal Medicine</i> , 2020, 75, 1-9.	1.0	26
84	Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 1875.	0.8	26
85	Anti-Hdv Immunoglobulin M Testing in Hepatitis Delta Revisited: Correlations with Disease Activity and Response to Pegylated Interferon-2A Treatment. <i>Antiviral Therapy</i> , 2012, 17, 305-312.	0.6	25
86	Low Serum Hepcidin in Patients with Autoimmune Liver Diseases. <i>PLoS ONE</i> , 2015, 10, e0135486.	1.1	25
87	Alterations of leptin during IFN- $\alpha$ therapy in patients with chronic viral hepatitis. <i>Journal of Hepatology</i> , 2006, 44, 848-855.	1.8	24
88	Molecular diagnostics of primary biliary cirrhosis. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 621-634.	1.6	23
89	Treatment of chronic hepatitis C with direct-acting antivirals in patients with $\beta$ -thalassaemia major and advanced liver disease. <i>British Journal of Haematology</i> , 2017, 178, 130-136.	1.2	23
90	Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure. <i>Cell Reports Medicine</i> , 2022, 3, 100560.	3.3	23

#	ARTICLE	IF	CITATIONS
91	Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. <i>Journal of Autoimmune Diseases</i> , 2007, 4, 2.	1.0	22
92	Anti- <i>Helicobacter pylori</i> antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific antimitochondrial antibodies. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1220.	0.8	22
93	Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants. <i>Journal of Viral Hepatitis</i> , 2020, 27, 699-708.	1.0	22
94	Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. <i>Turkish Journal of Gastroenterology</i> , 2012, 23, 560-568.	0.4	22
95	Development of antimitochondrial antibodies in patients with autoimmune hepatitis: Art of facts or an artifact?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 454-455.	1.4	21
96	Unusual cardiovascular complications of brucellosis presenting in two men: two case reports and a review of the literature. <i>Journal of Medical Case Reports</i> , 2011, 5, 22.	0.4	21
97	Permanent immunosuppression in SLA/LP $\alpha$ -positive autoimmune hepatitis is required although overall response and survival are similar. <i>Liver International</i> , 2020, 40, 368-376.	1.9	21
98	Features and outcome of AIH patients without elevation of IgG. <i>JHEP Reports</i> , 2020, 2, 100094.	2.6	21
99	ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients. <i>Journal of Innate Immunity</i> , 2022, 14, 218-228.	1.8	21
100	Use of TNF $\alpha$ antagonists in refractory AIH: Revealing the unforeseen. <i>Journal of Hepatology</i> , 2013, 59, 197-198.	1.8	20
101	Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. <i>Cancers</i> , 2021, 13, 1023.	1.7	20
102	Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. <i>European Journal of Internal Medicine</i> , 2009, 20, 35-43.	1.0	18
103	Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. <i>Clinica Chimica Acta</i> , 2010, 411, 411-415.	0.5	18
104	Reactivation of resolved hepatitis B virus infection after immunosuppression: Is it time to adopt pre-emptive therapy?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 84-93.	0.7	18
105	Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact?. <i>Annals of Hepatology</i> , 2013, 12, 147-151.	0.6	18
106	Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: Revealing the unforeseen. <i>Clinica Chimica Acta</i> , 2006, 373, 183-184.	0.5	17
107	Primary biliary cirrhosis and Henoch-Schonlein purpura: report of two cases and review of the literature. <i>Liver International</i> , 2007, 27, 280-283.	1.9	17
108	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	2.4	17

#	ARTICLE	IF	CITATIONS
109	Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. <i>World Journal of Hepatology</i> , 2013, 5, 577.	0.8	17
110	Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4894.	1.8	17
111	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2022, 75, 13-27.	3.6	16
112	MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19. <i>Immunobiology</i> , 2021, 226, 152136.	0.8	16
113	Impact of genetic and environmental factors on autoimmune hepatitis. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100125.	2.0	16
114	Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients. <i>World Journal of Gastroenterology</i> , 2012, 18, 4721.	1.4	16
115	Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. <i>Annals of Hepatology</i> , 2013, 13, 127-35.	0.6	16
116	Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. <i>European Journal of Internal Medicine</i> , 2021, 88, 52-62.	1.0	14
117	Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100321.	2.6	14
118	Anti-neutrophil antibodies in chronic viral hepatitis. <i>Journal of Hepatology</i> , 1994, 20, 561.	1.8	13
119	Leptin Receptor Isoforms mRNA Expression in Peripheral Blood Mononuclear Cells from Patients with Chronic Viral Hepatitis. <i>Experimental Biology and Medicine</i> , 2006, 231, 1653-1663.	1.1	13
120	An immunocompetent patient presenting with severe septic arthritis due to <i>Ralstonia pickettii</i> identified by molecular-based assays: a case report. <i>Cases Journal</i> , 2009, 2, 8125.	0.4	13
121	FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases. <i>Annals of Hepatology</i> , 2021, 22, 100285.	0.6	13
122	Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. <i>European Journal of Internal Medicine</i> , 2021, 85, 86-91.	1.0	13
123	Severe pharyngitis in stockbreeders: an unusual presentation of brucellosis. <i>Occupational Medicine</i> , 2008, 58, 305-307.	0.8	12
124	IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. <i>Clinica Chimica Acta</i> , 2012, 413, 1683-1688.	0.5	12
125	Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2019, 67, 197-211.	1.0	12
126	Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome. <i>Liver International</i> , 2021, 41, 1592-1599.	1.9	12



#	ARTICLE	IF	CITATIONS
127	Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials. <i>European Journal of Internal Medicine</i> , 2022, 101, 41-48.	1.0	12
128	Poor Stroke Risk Perception despite Moderate Public Stroke Awareness: Insight from a Cross-sectional National Survey in Greece. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 721-724.	0.7	11
129	Frequency of thyroid dysfunction after recombinant alpha-interferon therapy in Greek patients with chronic active hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 547-552.	0.8	10
130	Favourable outcome of life-threatening infectious-related haemophagocytic syndrome after combination treatment with corticosteroids and intravenous immunoglobulin infusions. <i>European Journal of Internal Medicine</i> , 2011, 22, e155-e157.	1.0	10
131	PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017003.	0.5	10
132	Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e25-e32.	0.7	10
133	Linking genetic variation with epigenetic profiles in Sjögren's syndrome. <i>Clinical Immunology</i> , 2020, 210, 108314.	1.4	10
134	Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer?. <i>Cancers</i> , 2021, 13, 3510.	1.7	10
135	First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients. <i>Frontiers in Immunology</i> , 2021, 12, 798602.	2.2	10
136	Spontaneous bacterial peritonitis: an unusual manifestation of brucellosis in a previous healthy male patient. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015209387-bcr2015209387.	0.2	9
137	Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and I $\gamma$ immunoglobulin infusions. <i>World Journal of Clinical Cases</i> , 2019, 7, 3394-3406.	0.3	9
138	Individualization of chronic hepatitis C treatment according to the host characteristics. <i>World Journal of Gastroenterology</i> , 2014, 20, 2839.	1.4	9
139	Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact?. <i>Annals of Hepatology</i> , 2013, 12, 147-51.	0.6	9
140	Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. <i>Liver International</i> , 2022, 42, 541-550.	1.9	9
141	How Common Are Connective Tissue Disorders in Patients with Autoimmune Hepatitis?. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 36, 332.	1.6	8
142	Celiac disease-related autoantibodies in end-stage autoimmune liver diseases: what is the message?. <i>Liver International</i> , 2008, 28, 426-428.	1.9	8
143	Decreased serum DNase1-activity in patients with autoimmune liver diseases. <i>Autoimmunity</i> , 2017, 50, 125-132.	1.2	8
144	Point-prevalence survey of healthcare facility-onset healthcare-associated <i>Clostridium difficile</i> infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. <i>PLoS ONE</i> , 2017, 12, e0182799.	1.1	8

#	ARTICLE	IF	CITATIONS
145	Postinfantile Giant Cell Hepatitis with Features of Acute Severe Autoimmune Hepatitis Probably Triggered by Diclofenac in a Patient with Primary Myelofibrosis. <i>Case Reports in Hepatology</i> , 2018, 2018, 1-5.	0.4	8
146	FRI-029-Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: important player or innocent bystander?. <i>Journal of Hepatology</i> , 2019, 70, e396-e397.	1.8	8
147	Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 855-859.	2.0	7
148	Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. <i>Liver International</i> , 2014, 34, 1207-1215.	1.9	7
149	Aiming towards hepatitis C virus elimination in Greece. <i>Annals of Gastroenterology</i> , 2019, 32, 321-329.	0.4	7
150	Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren's Syndrome and Primary Biliary Cholangitis. <i>Epigenomes</i> , 2019, 3, 15.	0.8	7
151	Plethora of Resistance Genes in Carbapenem-Resistant Gram-Negative Bacteria in Greece: No End to a Continuous Genetic Evolution. <i>Microorganisms</i> , 2022, 10, 159.	1.6	7
152	Bone marrow findings in patients with autoimmune liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, e416-21.	1.4	6
153	Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. <i>Liver International</i> , 2011, 31, 277-279.	1.9	6
154	Metabolic Acidosis during Treatment of Mushroom Poisoning: A Diagnostic Pitfall. <i>Internal Medicine</i> , 2012, 51, 1077-1080.	0.3	6
155	Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?. <i>Liver Transplantation</i> , 2019, 25, 1588-1589.	1.3	6
156	Promyelocytic leukemia antigen expression: A histological marker for primary biliary cholangitis diagnosis?. <i>Journal of Translational Internal Medicine</i> , 2021, 9, 43-51.	1.0	6
157	Management of patients with liver cirrhosis and invasive bladder cancer: A case-series. <i>Journal of Translational Internal Medicine</i> , 2019, 7, 29-33.	1.0	6
158	Soluble IL-2R Levels at Baseline Predict the Development of Severe Respiratory Failure and Mortality in COVID-19 Patients. <i>Viruses</i> , 2022, 14, 787.	1.5	6
159	Lack of association between appendectomy and primary biliary cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 573-576.	0.6	5
160	Cartilage oligomeric matrix protein on the spot for liver fibrosis evaluation: Too early or too late?. <i>European Journal of Internal Medicine</i> , 2017, 43, e48-e49.	1.0	5
161	" Type 1 autoimmune hepatitis presenting with severe autoimmune neutropenia". <i>Annals of Gastroenterology</i> , 2017, 31, 123-126.	0.4	5
162	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	2.6	5

#	ARTICLE	IF	CITATIONS
163	Early Primary Biliary Cirrhosis: A New Association with Erythema Nodosum of Unknown Origin. <i>Gastroenterology Research and Practice</i> , 2010, 2010, 1-4.	0.7	4
164	Severe liver involvement in two patients with long-term history of fever: remember familial Mediterranean fever. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216941.	0.2	4
165	Glycogenic hepatopathy as a cause of severe deranged liver enzymes in a young patient with type 1 diabetes mellitus. <i>BMJ Case Reports</i> , 2019, 12, e228524.	0.2	4
166	Variants of Primary Biliary Cholangitis: An Updated Mini-Review. <i>Journal of Autoimmune Diseases and Rheumatology</i> , 0, 6, 21-28.	0.2	4
167	Efficacy of Interferon A-2b Monotherapy in $\beta$ -Thalassemics with Chronic Hepatitis C. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 189-196.	0.5	4
168	Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. <i>Annals of Gastroenterology</i> , 2020, 34, 73-79.	0.4	4
169	Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5366.	1.0	4
170	Altered $\alpha$ -DNA methylation pattern characterizes the peripheral immune cells of patients with autoimmune hepatitis. <i>Liver International</i> , 2022, 42, 1355-1368.	1.9	4
171	Unexplained choroidal embolisation: remember the antiphospholipid syndrome. <i>Lancet</i> , The, 2006, 368, 1936.	6.3	3
172	Autoimmune hepatitis: Of host and pathogen. <i>Hepatology</i> , 2008, 47, 2147-2148.	3.6	3
173	Rifampicin: not always an innocent drug. <i>BMJ Case Reports</i> , 2018, 11, e227356.	0.2	3
174	CK18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission. <i>Liver International</i> , 2021, 41, 123-127.	1.9	3
175	Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220824.	0.2	3
176	Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. <i>BMJ Case Reports</i> , 2020, 13, e238400.	0.2	3
177	Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. <i>Annals of Gastroenterology</i> , 2017, 30, 542-549.	0.4	3
178	Could the 90s be a second childhood period? The case of Henoch-Schonlein purpura. <i>Age and Ageing</i> , 2008, 37, 483-483.	0.7	2
179	Can mathematical models be useful in clinical hepatology?. <i>Liver International</i> , 2010, 30, 637-638.	1.9	2
180	Editorial: autoimmune hepatitis – identifying options for treatment. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1237-1238.	1.9	2

#	ARTICLE	IF	CITATIONS
181	Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100126.	2.0	2
182	Spontaneous Cirrhosis Regression in an IFN-beta-induced AIH-like Syndrome Following Drug Withdrawal: Art of Facts or Artifacts?. <i>European Journal of Case Reports in Internal Medicine</i> , 2016, 3, 000396.	0.2	2
183	Hepcidin as a Sensitive and Treatment-Responsive Acute-Phase Marker in Patients with Bacteremia: A Pilot Study. <i>Diagnostics</i> , 2022, 12, 1404.	1.3	2
184	Which level of immunosuppression is harmful for occult hepatitis B virus infection?: A million dollar answer. <i>Liver International</i> , 2009, 29, 1127-1128.	1.9	1
185	Real-world experience from tenofovir alafenamide use in chronic hepatitis B: an Hellenic multicenter real-life clinical study (HERACLIS-TAF). <i>Journal of Hepatology</i> , 2020, 73, S865-S866.	1.8	1
186	An Immunocompetent HIV-Negative Elderly Patient with Low-Grade Fever, Generalized Lymphadenopathy, Splenomegaly, and Acute Phase Response: Do Not Forget Castleman Disease. <i>Case Reports in Infectious Diseases</i> , 2021, 2021, 1-7.	0.2	1
187	A chronic alcoholic man with high fever, neck rigidity and loss of consciousness: remember the Austrian syndrome a commonly unrecognised invasive pneumococcus triad. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-225010.	0.2	1
188	Reply to "Further considerations in autoimmune hepatitis". <i>Journal of Hepatology</i> , 2016, 64, 1458-1459.	1.8	0
189	p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 52-60.	1.0	0
190	The changing epidemiology of hepatitis B in Greece. <i>Annals of Gastroenterology</i> , 2021, 34, 431-437.	0.4	0
191	PSC-AIH Overlap. , 2020, , 359-373.		0
192	Hepatic brucellosis: a rare complication of a common zoonotic disease. <i>BMJ Case Reports</i> , 2020, 13, e237076.	0.2	0
193	Severe Pharyngodynia Followed by Migratory Polyarthritits and High Fever in Young Immigrants: Remember That Rheumatic Fever Is Still Relevant in 2020!. <i>Case Reports in Infectious Diseases</i> , 2020, 2020, 1-6.	0.2	0
194	521. Similarities and Differences in Transcriptomic Host Response between SARS-CoV-2 and Other Viral Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, S326-S327.	0.4	0